Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
1799 studies found for:    "Pancreatic cancer"
Show Display Options
Rank Status Study
21 Completed
Has Results
Study of Low-Dose Fractionated Radiotherapy in Patients With Locally Advanced Metastatic Pancreatic Cancer
Conditions: Pancreatic Carcinoma Non-resectable;   Metastatic Pancreatic Cancer
Interventions: Drug: gemcitabine;   Drug: Erlotinib;   Radiation: low dose fractionated radiotherapy
22 Terminated Clinical Trial of High-dose Vitamin C for Advanced Pancreatic Cancer
Conditions: Pancreatic Neoplasms;   Pancreatic Cancer
Intervention: Drug: Gemcitabine with escalating ascorbic acid
23 Terminated Study With Gemcitabine and RTA 402 for Patients With Unresectable Pancreatic Cancer
Conditions: Pancreatic Neoplasms;   Pancreatic Cancer
Interventions: Drug: Bardoxolone methyl;   Drug: Gemcitabine;   Drug: Placebo
24 Terminated Immunotherapy and SBRT Study in Borderline Resectable Pancreatic Cancer
Conditions: Pancreatic Cancer;   Pancreatic Carcinoma Non-resectable
Interventions: Drug: mFOLFIRINOX;   Biological: Algenpantucel-L Immunotherapy;   Radiation: SBRT;   Drug: Gemcitabine
25 Active, not recruiting Immunotherapy Study in Borderline Resectable or Locally Advanced Unresectable Pancreatic Cancer
Conditions: Pancreatic Cancer;   Pancreatic Carcinoma Non-resectable;   Locally Advanced Malignant Neoplasm
Interventions: Drug: FOLFIRINOX;   Biological: Algenpantucel-L Immunotherapy;   Radiation: 5-FU Chemoradiation;   Drug: Gemcitabine;   Drug: Capecitabine;   Drug: Nab-Paclitaxel
26 Completed
Has Results
Paclitaxel and Bryostatin 1 in Treating Patients With Advanced Pancreatic Cancer
Conditions: Acinar Cell Adenocarcinoma of the Pancreas;   Duct Cell Adenocarcinoma of the Pancreas;   Recurrent Pancreatic Cancer;   Stage III Pancreatic Cancer;   Stage IV Pancreatic Cancer
Interventions: Drug: paclitaxel;   Drug: bryostatin 1
27 Completed Bevacizumab and Gemcitabine in Treating Patients With Advanced Pancreatic Cancer
Conditions: Adenocarcinoma of the Pancreas;   Recurrent Pancreatic Cancer;   Stage III Pancreatic Cancer;   Stage IV Pancreatic Cancer
Interventions: Drug: gemcitabine hydrochloride;   Biological: bevacizumab;   Other: laboratory biomarker analysis
28 Recruiting Alisertib and Gemcitabine Hydrochloride in Treating Patients With Solid Tumors or Pancreatic Cancer
Conditions: Acinar Cell Adenocarcinoma of the Pancreas;   Duct Cell Adenocarcinoma of the Pancreas;   Recurrent Pancreatic Cancer;   Stage III Pancreatic Cancer;   Stage IV Pancreatic Cancer;   Unspecified Adult Solid Tumor, Protocol Specific
Interventions: Drug: alisertib;   Drug: gemcitabine
29 Active, not recruiting Dinaciclib and Akt Inhibitor MK2206 in Treating Patients With Pancreatic Cancer That Cannot Be Removed by Surgery
Conditions: Pancreatic Adenocarcinoma;   Recurrent Pancreatic Carcinoma;   Stage III Pancreatic Cancer;   Stage IV Pancreatic Cancer;   Unresectable Pancreatic Carcinoma
Interventions: Drug: Akt Inhibitor MK2206;   Drug: Dinaciclib;   Other: Laboratory Biomarker Analysis;   Other: Pharmacological Study
30 Not yet recruiting Ascorbic Acid and Combination Chemotherapy in Treating Patients With Locally Advanced or Recurrent Pancreatic Cancer That Cannot Be Removed by Surgery
Conditions: Pancreatic Adenocarcinoma;   Recurrent Pancreatic Carcinoma;   Stage III Pancreatic Cancer;   Stage IV Pancreatic Cancer;   Unresectable Pancreatic Carcinoma
Interventions: Drug: Oxaliplatin;   Drug: Irinotecan Hydrochloride;   Drug: Leucovorin Calcium;   Drug: Fluorouracil;   Dietary Supplement: Ascorbic Acid
31 Completed Erlotinib, Gemcitabine, and Radiation Therapy in Treating Patients With Locally Advanced Unresectable Pancreatic Cancer
Conditions: Adenocarcinoma of the Pancreas;   Recurrent Pancreatic Cancer;   Stage II Pancreatic Cancer;   Stage III Pancreatic Cancer
Interventions: Drug: erlotinib hydrochloride;   Drug: gemcitabine hydrochloride;   Radiation: radiation therapy;   Other: laboratory biomarker analysis
32 Recruiting Combination Chemotherapy Before and After Surgery in Treating Patients With Localized Pancreatic Cancer
Conditions: Acinar Cell Adenocarcinoma of the Pancreas;   Duct Cell Adenocarcinoma of the Pancreas;   Stage I Pancreatic Cancer;   Stage IIA Pancreatic Cancer;   Stage IIB Pancreatic Cancer
Interventions: Drug: oxaliplatin;   Drug: leucovorin calcium;   Drug: irinotecan hydrochloride;   Drug: fluorouracil;   Procedure: therapeutic conventional surgery;   Other: laboratory biomarker analysis
33 Withdrawn Dovitinib Lactate, Gemcitabine Hydrochloride, and Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With Advanced Solid Tumors or Pancreatic Cancer
Conditions: Duct Cell Adenocarcinoma of the Pancreas;   Recurrent Pancreatic Cancer;   Stage III Pancreatic Cancer;   Stage IV Pancreatic Cancer;   Unspecified Adult Solid Tumor, Protocol Specific
Interventions: Drug: dovitinib lactate;   Drug: gemcitabine hydrochloride;   Drug: paclitaxel albumin-stabilized nanoparticle formulation;   Other: pharmacological study;   Other: laboratory biomarker analysis
34 Recruiting BVD-523 Plus Nab-paclitaxel and Gemcitabine in Patients With Metastatic Pancreatic Cancer
Conditions: Pancreatic Cancer;   Cancer of Pancreas;   Cancer of the Pancreas;   Pancreas Cancer
Interventions: Drug: BVD-523;   Drug: Nab-paclitaxel;   Drug: Gemcitabine
35 Recruiting Pancreatic Cancer Early Detection Program
Conditions: Pancreatic Cancer;   Pancreas Cancer;   Pancreatic Adenocarcinoma;   Familial Pancreatic Cancer;   BRCA 1/2;   HNPCC;   Lynch Syndrome;   Hereditary Pancreatitis;   FAMMM;   Familial Atypical Multiple Mole Melanoma;   Peutz Jeghers Syndrome
Interventions: Procedure: Endoscopic Ultrasound;   Procedure: Magnetic Resonance Imaging (MRI)
36 Completed UCN-01 and Gemcitabine in Treating Patients With Unresectable or Metastatic Pancreatic Cancer
Conditions: Adenocarcinoma of the Pancreas;   Recurrent Pancreatic Cancer;   Stage II Pancreatic Cancer;   Stage III Pancreatic Cancer;   Stage IV Pancreatic Cancer
Interventions: Drug: 7-hydroxystaurosporine;   Drug: gemcitabine hydrochloride;   Other: pharmacological study;   Other: laboratory biomarker analysis
37 Terminated RO4929097 Before Surgery in Treating Patients With Pancreatic Cancer
Conditions: Adenocarcinoma of the Pancreas;   Stage IA Pancreatic Cancer;   Stage IB Pancreatic Cancer;   Stage IIA Pancreatic Cancer;   Stage IIB Pancreatic Cancer
Interventions: Drug: gamma-secretase/Notch signalling pathway inhibitor RO4929097;   Other: laboratory biomarker analysis;   Other: pharmacological study;   Procedure: neoadjuvant therapy;   Procedure: therapeutic conventional surgery
38 Recruiting Neoadjuvant Chemotherapy Followed by Concurrent Chemoradiation With Gemcitabine, Sorafenib and Vorinostat in Resectable, Borderline Resectable or Unresectable Non-metastatic Pancreas Cancer
Conditions: Pancreatic Adenocarcinoma;   Stage IA Pancreatic Cancer;   Stage IB Pancreatic Cancer;   Stage IIA Pancreatic Cancer;   Stage IIB Pancreatic Cancer;   Stage III Pancreatic Cancer
Interventions: Drug: Gemcitabine;   Drug: Sorafenib;   Drug: Vorinostat;   Radiation: 3-Dimensional Conformal Radiation Therapy;   Radiation: Intensity-Modulated Radiation Therapy;   Other: RosetteSep;   Other: DEPfff
39 Active, not recruiting Pancreatic Cancer Genetic Epidemiology (PACGENE) Study
Condition: Pancreatic Cancer
Intervention: Behavioral: Questionnaire
40 Completed Phase I Study of Stereotactic Body Radiation Therapy and FOLFIRINOX in the Neoadjuvant Therapy of Pancreatic Cancer
Conditions: Cancer of Pancreas;   Cancer of the Pancreas;   Neoplasms, Pancreatic;   Pancreas Cancer;   Pancreas Neoplasms
Interventions: Drug: Modified FOLFIRINOX;   Radiation: Stereotactic Body Radiotherapy (SBRT)

First Page    Show previous page of results Previous Page (1-20) Studies Shown (21-40) Next Page (41-60) Show next page of results    Last Page
Indicates status has not been verified in more than two years